Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer
- Karen E Hoffman 1, David F Penson 2, Zhiguo Zhao 3, Li-Ching Huang 3, Ralph Conwill 4, Aaron A Laviana 2, Daniel D Joyce 2, Amy N Luckenbaugh 2, Michael Goodman 5, Ann S Hamilton 6, Xiao-Cheng Wu 7, Lisa E Paddock 8, Antoinette Stroup 8, Matthew R Cooperberg 9, Mia Hashibe 10, Brock B O'Neil 11, Sherrie H Kaplan 12, Sheldon Greenfield 12, Tatsuki Koyama 3, Daniel A Barocas 2
- Karen E Hoffman 1, David F Penson 2, Zhiguo Zhao 3
- 1Department of Radiation Oncology, The University of Texas MD Anderson Center, Houston.
- 2Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
- 3Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
- 4Office of Patient and Community Education, Patient Advocacy Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
- 5Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia.
- 6Department of Preventative Medicine, Keck School of Medicine at the University of Southern California, Los Angeles.
- 7Department of Epidemiology, Louisiana State University New Orleans School of Public Health, New Orleans.
- 8Department of Epidemiology, Cancer Institute of New Jersey, Rutgers Health, New Brunswick.
- 9Department of Urology, University of California, San Francisco.
- 10Department of Family and Preventative Medicine, University of Utah School of Medicine, Salt Lake City.
- 11Department of Urology, University of Utah Health, Salt Lake City.
- 12Department of Medicine, University of California Irvine, Irvine.
- 0Department of Radiation Oncology, The University of Texas MD Anderson Center, Houston.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.For localized prostate cancer, most treatment side effects on function improve over 5 years. However, prostatectomy leads to lasting urinary incontinence, and worse sexual function in unfavorable-risk cases compared to radiation therapy.
Area Of Science
- Oncology
- Urology
- Health Services Research
Background
- Understanding long-term functional outcomes of prostate cancer treatments is crucial for informed treatment selection.
- Contemporary treatments for localized prostate cancer include active surveillance, surgery, and radiation therapy, each with potential adverse effects.
Purpose Of The Study
- To compare patient-reported functional outcomes over 5 years following treatment for favorable-risk and unfavorable-risk localized prostate cancer.
Main Methods
- A prospective, population-based cohort study included 2005 men diagnosed with localized prostate cancer between 2011-2012.
- Functional outcomes were assessed using the Expanded Prostate Index Composite (EPIC) up to 5 years post-treatment.
- Regression models were adjusted for baseline function and patient/tumor characteristics.
Main Results
- For favorable-risk disease, nerve-sparing prostatectomy was linked to worse urinary incontinence and sexual function compared to active surveillance.
- Low-dose-rate brachytherapy showed worse urinary, sexual, and bowel function at 1 year versus active surveillance.
- For unfavorable-risk disease, prostatectomy resulted in worse incontinence and sexual function compared to external beam radiation therapy with androgen deprivation therapy (EBRT with ADT) at 5 years.
Conclusions
- Most functional differences between prostate cancer treatments diminish by 5 years.
- Prostatectomy consistently led to clinically meaningful worse incontinence through 5 years.
- For unfavorable-risk disease, prostatectomy resulted in worse sexual function at 5 years compared to EBRT with ADT.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
01:21
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:20
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

